Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-0.21%
1,091.51
-2.30
-0.21%
—1,093.811,096.521,100.221,091.51——
SIXC
Communications
SIXC
Communications
SIXC
+0.22%
610.11
+1.34
+0.22%
—608.77608.77612.97608.77——
SIXE
Energy
SIXE
Energy
SIXE
-1.34%
1,237.98
-16.83
-1.34%
—1,254.811,253.011,253.871,226.33——
SIXI
Industrials
SIXI
Industrials
SIXI
-0.93%
1,744.71
-16.40
-0.93%
—1,761.111,764.271,766.881,744.71——
SIXM
Financials
SIXM
Financials
SIXM
-0.37%
640.18
-2.40
-0.37%
—642.58644.87648.48640.18——
SIXR
Staples
SIXR
Staples
SIXR
-0.18%
849.58
-1.55
-0.18%
—851.13855.66858.75845.56——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-0.23%
217.48
-0.50
-0.23%
—217.98217.98218.65216.88——
SIXT
Technology
SIXT
Technology
SIXT
+1.52%
3,260.69
+48.86
+1.52%
—3,211.833,227.213,268.383,226.55——
SIXU
Utilities
SIXU
Utilities
SIXU
-0.69%
942.45
-6.53
-0.69%
—948.98948.58957.83941.97——
SIXV
Health care
SIXV
Health care
SIXV
-0.52%
1,466.80
-7.72
-0.52%
—1,474.521,479.031,481.041,466.80——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+0.22%
2,397.50
+5.38
+0.22%
—2,392.122,396.952,421.222,382.32——
AMG0:FRA
Amgen CAD Hedged CIBC CDR
€15.70
-1.88%
(-0.30) 1D
Apr 30, 10:00:00 PM GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for AMG0...
Open
€15.70
High
€15.70
Low
€15.70
Mkt. cap
178.00B
Avg. vol.
1.00
Volume
0.00
52-wk high
€18.00
52-wk low
€12.30
No. of employees
32K
News stories
From sources across the web
Profile
Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company is ranked 18th on the list of largest biomedical companies by revenue. The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics. The company's major products are Prolia and XGEVA for treatment of osteoporosis and bone diseases, Enbrel for treatment of autoimmune diseases, Repatha for treatment of hyperlipidemia, Otezla for treatment of psoriasis and psoriatic arthritis, Tepezza to treat Graves' ophthalmopathy, Evenity to treat osteoporosis, Kyprolis to treat cancer, Nplate to regulate platelet production, and Aranesp to stimulate erythropoiesis. Amgen has 17 clinical programs underway in Phase III, eight in Phase II, and 19 in Phase I. Its pipeline includes MariTide, an anti-obesity medication administered once per month by injection. The company receives approximately 80% of its revenues from sales to the three large U.S. drug wholesalers: McKesson Corporation, Cencora, and Cardinal Health. The company is ranked 134th on the Fortune 500 and 202nd on the Forbes Global 2000. Wikipedia
About Amgen CAD Hedged CIBC CDR
CEORobert A. Bradway
Employees31.5K
FoundedApr 8, 1980
HeadquartersThousand Oaks, California, United States
SectorBiotechnology
Websiteamgen.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
9.18B
9.56B
9.87B
8.62B
Cost of goods sold
2.67B
2.74B
2.68B
2.74B
Cost of revenue
2.67B
2.74B
2.68B
2.74B
Research and development expenses
1.74B
1.90B
2.14B
1.72B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1.69B
1.72B
1.95B
1.58B
Operating expense
3.50B
3.55B
4.18B
3.17B
Total operating expenses
6.18B
6.29B
6.85B
5.95B
Operating income
3.00B
3.26B
3.01B
2.67B
Other non operating income
-113.00M
181.00M
143.00M
75.00M
EBT including unusual items
1.57B
3.92B
1.51B
2.08B
EBT excluding unusual items
2.37B
2.72B
2.51B
2.08B
Income tax expense
136.00M
705.00M
181.00M
265.00M
Effective tax rate
8.67%
17.98%
11.96%
12.72%
Other operating expenses
68.00M
-71.00M
82.00M
-133.00M
Net income
1.43B
3.22B
1.33B
1.82B
Net profit margin
15.60%
33.65%
13.51%
21.11%
Earnings per share
6.02
5.64
5.29
5.15
Interest and investment income
-
-
408.00M
-
Interest expense
-694.00M
-685.00M
-1.06B
-657.00M
Net interest expenses
-694.00M
-685.00M
-653.00M
-657.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
4.34B
4.57B
4.02B
3.93B
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer